Literature DB >> 7679711

Functional expression of B7/BB1 on activated T lymphocytes.

M Azuma1, H Yssel, J H Phillips, H Spits, L L Lanier.   

Abstract

B7/BB1 is a membrane differentiation antigen expressed on activated B cells, macrophages, and dendritic cells that binds to a counter-receptor, CD28, expressed on T lymphocytes and thymocytes. Interaction between CD28 and B7 results in potent costimulation of T cell activation initiated via the CD3/T cell receptor complex. We now report that B7 is also expressed on activated human peripheral blood T cells, CD4 T cell clones, CD8 T cell clones, and natural killer cell clones. B7 appears relatively late after T cell activation, can be detected on both CD4 and CD8 T cell subsets, and is present on antigen-specific, major histocompatibility complex-restricted CD4 and CD8 T cell clones. Expression of B7 on activated T cells was confirmed by immunoprecipitation from 125I-labeled activated T cells and by detection of B7 transcripts. A B7+ CD4+ T cell clone was able to stimulate a primary allogeneic mixed lymphocyte response using small, resting peripheral blood T cells as responders. The alloantigen-induced proliferative response and cytokine production was partially inhibited by anti-B7 monoclonal antibody. Since activated T cells can coexpress both CD28 and its counter-receptor, B7, this suggests that activated T cells may be capable of autocrine costimulation via the CD28 activation pathway.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7679711      PMCID: PMC2190946          DOI: 10.1084/jem.177.3.845

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  27 in total

1.  T cell clones which share T cell receptor epitopes differ in phenotype, function and specificity.

Authors:  H Yssel; D Blanchard; A Boylston; J E De Vries; H Spits
Journal:  Eur J Immunol       Date:  1986-10       Impact factor: 5.532

2.  B7/BB1, the ligand for CD28, is expressed on repeatedly activated human T cells in vitro.

Authors:  D M Sansom; N D Hall
Journal:  Eur J Immunol       Date:  1993-01       Impact factor: 5.532

3.  B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells.

Authors:  G J Freeman; A S Freedman; J M Segil; G Lee; J F Whitman; L M Nadler
Journal:  J Immunol       Date:  1989-10-15       Impact factor: 5.422

4.  B7, a B-cell-restricted antigen that identifies preactivated B cells.

Authors:  A S Freedman; G Freeman; J C Horowitz; J Daley; L M Nadler
Journal:  J Immunol       Date:  1987-11-15       Impact factor: 5.422

5.  Activated human T cells can present denatured antigen.

Authors:  T L Gerrard; D J Volkman; C H Jurgensen; A S Fauci
Journal:  Hum Immunol       Date:  1986-12       Impact factor: 2.850

6.  Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway.

Authors:  T Lindstein; C H June; J A Ledbetter; G Stella; C B Thompson
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

7.  B lymphoblast antigen (BB-1) expressed on Epstein-Barr virus-activated B cell blasts, B lymphoblastoid cell lines, and Burkitt's lymphomas.

Authors:  T Yokochi; R D Holly; E A Clark
Journal:  J Immunol       Date:  1982-02       Impact factor: 5.422

8.  T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression.

Authors:  C H June; J A Ledbetter; M M Gillespie; T Lindsten; C B Thompson
Journal:  Mol Cell Biol       Date:  1987-12       Impact factor: 4.272

9.  The T cell antigen receptor complex expressed on normal peripheral blood CD4-, CD8- T lymphocytes. A CD3-associated disulfide-linked gamma chain heterodimer.

Authors:  L L Lanier; N A Federspiel; J J Ruitenberg; J H Phillips; J P Allison; D Littman; A Weiss
Journal:  J Exp Med       Date:  1987-04-01       Impact factor: 14.307

10.  Human T cell activation. II. A new activation pathway used by a major T cell population via a disulfide-bonded dimer of a 44 kilodalton polypeptide (9.3 antigen).

Authors:  T Hara; S M Fu; J A Hansen
Journal:  J Exp Med       Date:  1985-06-01       Impact factor: 14.307

View more
  58 in total

Review 1.  The contributions of T-cell anergy to peripheral T-cell tolerance.

Authors:  R Lechler; J G Chai; F Marelli-Berg; G Lombardi
Journal:  Immunology       Date:  2001-07       Impact factor: 7.397

2.  Expression of both B7-1 and CD28 contributes to the IL-2 responsiveness of CTLL-2 cells.

Authors:  R Belani; G J Weiner
Journal:  Immunology       Date:  1996-02       Impact factor: 7.397

3.  Treatment with anti-CD86 costimulatory molecule prevents the autoimmune lesions in murine Sjögren's syndrome (SS) through up-regulated Th2 response.

Authors:  K Saegusa; N Ishimaru; K Yanagi; N Haneji; M Nishino; M Azuma; I Saito; Y Hayashi
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

4.  Activation antigens on colonic T cells in inflammatory bowel disease: effects of IL-10.

Authors:  E C Ebert; V Mehta; K M Das
Journal:  Clin Exp Immunol       Date:  2005-04       Impact factor: 4.330

5.  Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.

Authors:  James N Kochenderfer; Steven A Feldman; Yangbing Zhao; Hui Xu; Mary A Black; Richard A Morgan; Wyndham H Wilson; Steven A Rosenberg
Journal:  J Immunother       Date:  2009-09       Impact factor: 4.456

6.  Down-regulation of Th2 responses by Brucella abortus, a strong Th1 stimulus, correlates with alterations in the B7.2-CD28 pathway.

Authors:  I Agranovich; D E Scott; D Terle; K Lee; B Golding
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

7.  Tolerogenicity of resting and activated B cells.

Authors:  K M Gilbert; W O Weigle
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

Review 8.  Involvement of CD80 in the generation of CD4+ cytotoxic T cells.

Authors:  D Mauri; W J Pichler
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

Review 9.  CD28 Costimulation: From Mechanism to Therapy.

Authors:  Jonathan H Esensten; Ynes A Helou; Gaurav Chopra; Arthur Weiss; Jeffrey A Bluestone
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

Review 10.  New insights into tumor-host interactions in lymphoma metastasis.

Authors:  V Umansky; V Schirrmacher; M Rocha
Journal:  J Mol Med (Berl)       Date:  1996-07       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.